Jafra Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Jafra Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-30,375	Closed	-$4.95M	–	111
2018 Q1	$4.95M	Buy	+30,375	New	+$4.96M	1.54%	17
2017 Q2	–	Sell	-17,690	Closed	-$1.93M	–	89
2017 Q1	$1.93M	Buy	17,690 +7,690	+77%	+$677K	0.78%	37
2016 Q4	$737K	Buy	+10,000	New	+$814K	0.62%	54

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jafra Capital Management's VRTX Position: Q2 2018 in Review

Jafra Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 30,375 shares — an estimated $4.95M sold.

Jafra Capital Management first reported a position in VRTX in Q4 2016 and held it in 3 quarters. The position peaked at $4.95M in Q1 2018. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Jafra Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Jafra Capital Management sold 30,375 Vertex Pharmaceuticals shares in Q2 2018, an estimated $4.95M.
Jafra Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Jafra Capital Management's Vertex Pharmaceuticals position peaked at $4.95M in Q1 2018.
689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Jafra Capital Management's 13F filing for Q2 2018, filed 15 Aug 2018.